The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1444
Sublingual Immunotherapy for Allergic Rhinitis
The full article is available to subscribers Subscriber Login   

The FDA has approved 3 allergen extracts for sublingual administration as immunotherapy for allergic rhinitis confirmed by a positive skin test or in vitro testing for pollen-specific IgE antibodies: Oralair (Stallergenes S.A./Greer) and Grastek (Merck) for grass pollen-induced allergic rhinitis and Ragwitek (Merck) for short ragweed pollen-induced allergic rhinitis.

ALLERGIC RHINITIS — Orally administered second-generation H1-antihistamines are the preferred first-line therapy for relief of itching, sneezing, and rhinorrhea associated with mild to moderate allergic rhinitis. Intranasal corticosteroids are the most effective drugs available for prevention and relief of allergic rhinitis symptoms, including itching, sneezing, discharge, and congestion, and are the drugs of choice for moderate to severe disease. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Sublingual Immunotherapy for Allergic Rhinitis
Article code: 1444c
 Electronic, downloadable article - $35
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian